1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Two: Mid-Table Firms Move Up And Down

As Certain Companies Ascend, Others Are Moving In The Opposite Direction

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we look at the mid-table players and how they have shifted positions this year.

Generics Bulletin Top 50 2023
Ups and downs have been seen in the middle of our ranking • Source: Shutterstock

With two new spaces having opened up in our rundown of the top 10 generics and biosimilars companies this year – allowing Dr Reddy’s and Cipla to ascend out of the middle table covering positions 11-30 in our ranking, and into the top 10 (see sidebar) – this has left room for further firms to climb up the charts in the second part of the Generics Bulletin Top 50.

Intas – parent company of Accord – now tops the second table, providing financial details directly to Generics Bulletin. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

More from Market Intelligence

Trimethoprim Trebles As Last Month’s UK Fallers Bounce Back

 
• By Dave Wallace

In a month that saw the average prices of five generic presentations more than double in the UK, WaveData’s figures showed trimethoprim leading the rises with an enormous price increase in February, as several products bounced back from declines in the previous month.

Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

 
• By Dave Wallace

Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.

Vardenafil Leads UK Rises In January

 
• By Dave Wallace

Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.